Cystic Fluid and Platinum Levels in Ovarian Cancer
Author Information
Author(s): M.D. Shelley, R.G. Fish, M. Adams, I. Kerby
Primary Institution: South Wales Radiotherapy and Oncology Service, Velinde Hospital, Cardiff
Hypothesis
The study investigates the variability of cis-dichlorodiamine platinum (CDDP) levels in cystic fluid and plasma of ovarian cancer patients.
Conclusion
The availability of active platinum species in cystic fluid is less than previously anticipated, indicating variability in drug exposure among patients.
Supporting Evidence
- Platinum levels in cystic fluid were found to be variable between patients.
- Peak platinum levels occurred at the end of drug infusion.
- Non-protein bound platinum concentrations declined rapidly after infusion.
Takeaway
This study looked at how a cancer drug spreads in the body of three patients, finding that the amount of the drug available to fight the cancer can be very different from person to person.
Methodology
The study measured total and non-protein bound platinum levels in plasma and cystic fluid after administering CDDP to patients.
Limitations
The study had a small sample size and variability in drug exposure was noted, which may affect the generalizability of the results.
Participant Demographics
Three patients with Stage I cystadenocarcinoma of the ovary.
Want to read the original?
Access the complete publication on the publisher's website